Prothrombinex use for the reversal of warfarin: Is fresh frozen plasma needed? [2]

Medical Journal of Australia

Volumn 184, Issue 7, 2006, Pages 365-366

  Crawford, Julie H ^a,b   Augustson, Bradley M ^a,b  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR; FRESH FROZEN PLASMA; PROTHROMBINEX; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING DISORDER; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CONTROLLED STUDY; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE REPLACEMENT; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; MAJOR CLINICAL STUDY; VENOUS THROMBOEMBOLISM;

EID: 33645767960     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2006.tb00277.x     Document Type: Letter

References (3)

1. Baker RI, Gallus AS, Harper PL, et al. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-497.
2. MIMS Australia. Prothrombinex-HT. MIMS annual. Sydney: MediMedia Australia, June 2004: 2-252.
3. Levine M, Raskob G, Landerfeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119: 108S-121S.